News

Oxthera: Funds for orphan drug
Enlarge image

FincanceSwedenFrance

Oxthera: Funds for orphan drug

18.04.2014 - Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

Stockholm-based Oxthera announced that they have received the financing from a syndicate of current shareholders and new investors, led by French Kurma Partners, including Idinvest Partners and Mayo Clinic. Oxthera is currently conducting a phase II clinical study to demonstrate the clinical efficacy of their product Oxabact in primary hyperoxaluria, which is a rare autosomal recessive disorder. The disease leads to markedly elevated levels of endogenous oxalate in plasma and urine, which in turn can cause kidney damage, including calcification of the kidney. If left untreated, the disease can cause kidney failure and premature death.

Since primary hyperoxaluria affects only about 3,000 patients in the Western world, Oxabact has received orphan drug designation in the EU and the US for this indication. Clinical trials with Oxabact in patients with the disorder were initiated in 2013 at seven clinical sites in three countries. Results are expected during autumn of this year. The oral product is composed of highly concentrated freeze-dried live bacteria (Oxalobacter formigenes). With Oxazyme, Oxathera also has another drug in the pipeline: The oxalate decarboxylase is used for the treatment of oxalate malabsorption and kidney failure in enteric hyperoxaluria.

After the financing round, Oxthera’s board of directors will be joined by Khalid Islam, previously Chairman a CEO of Gentium S.p.A., and Rémi Droller, Managing Partner of Kurma Partners. “I am pleased to join the Board and look forward to assisting the management in their efforts to provide a much needed therapy for patients with this devastating disease, a high unmet medical need given that currently there are no approved therapies”, Islam commented.

© eurobiotechnews.eu/um

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PHARMING (NL)0.53 EUR12.8%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • NICOX (F)2.44 EUR7.5%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • DEINOVE (F)12.96 EUR-5.3%

TOP

  • BIOTECH PHARMACON (N)17.50 NOK59.1%
  • WILEX (D)0.92 EUR53.3%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-44.9%
  • PROTHENA PLC (IE)28.07 USD-40.8%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.53 EUR783.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 19.04.2014